RSS
Mewburn Ellis
Opening the floodgates: Looking at the innovation and IP of immunotherapies
In this article, Frances Salisbury (partner) and Adam Gregory (associate) — European Patent Attorneys in the Life Sciences team at Mewburn Ellis — discuss innovation and IP of CAR-T therapies in more detail. more
The biotech revolution: Risks and opportunities of the growing trend
Recently, there has been a shift within the pharmaceutical industry veering its R&D away from the traditional corporate campuses and moving them to new collaborative biotech clusters. Nick Sutcliffe, discusses the risks and opportunities of the trend more
